Alkermes Stock Forecast, Price & News

-0.27 (-1.09 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.55 million shs
Average Volume1.54 million shs
Market Capitalization$3.92 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ALKS News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

Alkermes logo

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI (olanzapine/samidorphan), an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; a license agreement with Acorda Therapeutics, Inc.; and a license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.22 out of 5 stars

Medical Sector

950th out of 2,100 stocks

Pharmaceutical Preparations Industry

461st out of 831 stocks

Analyst Opinion: 1.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Alkermes (NASDAQ:ALKS) Frequently Asked Questions

Is Alkermes a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Alkermes stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALKS, but not buy additional shares or sell existing shares.
View analyst ratings for Alkermes
or view top-rated stocks.

What stocks does MarketBeat like better than Alkermes?

Wall Street analysts have given Alkermes a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Alkermes wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Alkermes' next earnings date?

Alkermes is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Alkermes

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) announced its quarterly earnings results on Tuesday, April, 27th. The company reported $0.11 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.02) by $0.13. The business earned $251.43 million during the quarter, compared to the consensus estimate of $233.78 million. Alkermes had a negative net margin of 9.06% and a negative trailing twelve-month return on equity of 0.15%. The business's revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.01 earnings per share.
View Alkermes' earnings history

How has Alkermes' stock been impacted by Coronavirus?

Alkermes' stock was trading at $16.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALKS stock has increased by 50.3% and is now trading at $24.42.
View which stocks have been most impacted by COVID-19

What guidance has Alkermes issued on next quarter's earnings?

Alkermes issued an update on its FY 2021 earnings guidance on Wednesday, May, 5th. The company provided EPS guidance of 0.370-0.620 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.470. The company issued revenue guidance of $1.10 billion-$1.17 billion, compared to the consensus revenue estimate of $1.12 billion.

What price target have analysts set for ALKS?

6 analysts have issued 1 year target prices for Alkermes' shares. Their forecasts range from $15.00 to $29.00. On average, they expect Alkermes' stock price to reach $22.20 in the next twelve months. This suggests that the stock has a possible downside of 9.1%.
View analysts' price targets for Alkermes
or view top-rated stocks among Wall Street analysts.

Who are Alkermes' key executives?

Alkermes' management team includes the following people:
  • Mr. Richard F. Pops, Chairman & CEO (Age 59, Pay $2M)
  • Mr. David Joseph Gaffin, Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 49, Pay $839.91k) (LinkedIn Profile)
  • Mr. Michael J. Landine, Sr. VP of Corp. Devel. & Chief Risk Officer (Age 67, Pay $750.46k)
  • Dr. Craig C. Hopkinson, Exec. VP of R&D and Chief Medical Officer (Age 53, Pay $1.02M)
  • Dr. Floyd E. Bloom, Founder (Age 84)
  • Mr. Iain Michael Brown, Sr. VP & CFO (Age 52)
  • Mr. Blair C. Jackson, Exec. VP & COO (Age 48)
  • Ms. Sandra Coombs, Co-Head of Investor Relations
  • Ms. Eva Stroynowski, VP of Product & R&D Communications, Public Affairs
  • Mr. Stephen Schiavo, Sr. VP of HR

What is Richard F. Pops' approval rating as Alkermes' CEO?

119 employees have rated Alkermes CEO Richard F. Pops on Richard F. Pops has an approval rating of 84% among Alkermes' employees.

Who are some of Alkermes' key competitors?

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), (CELG), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Who are Alkermes' major shareholders?

Alkermes' stock is owned by a variety of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (14.80%), BlackRock Inc. (5.85%), Primecap Management Co. CA (4.16%), Renaissance Technologies LLC (3.78%), Camber Capital Management LP (3.49%) and Armistice Capital LLC (2.20%). Company insiders that own Alkermes stock include Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops and Wendy L Dixon.
View institutional ownership trends for Alkermes

Which major investors are selling Alkermes stock?

ALKS stock was sold by a variety of institutional investors in the last quarter, including Woodline Partners LP, Camber Capital Management LP, UBS Group AG, Goldman Sachs Group Inc., Renaissance Technologies LLC, Arrowstreet Capital Limited Partnership, Citigroup Inc., and Nomura Holdings Inc.. Company insiders that have sold Alkermes company stock in the last year include Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Iain Michael Brown, Michael J Landine, Richard F Pops, and Wendy L Dixon.
View insider buying and selling activity for Alkermes
or view top insider-selling stocks.

Which major investors are buying Alkermes stock?

ALKS stock was bought by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Artisan Partners Limited Partnership, Bank of New York Mellon Corp, Millennium Management LLC, Seizert Capital Partners LLC, UBS Asset Management Americas Inc., Point72 Asset Management L.P., and Dimensional Fund Advisors LP.
View insider buying and selling activity for Alkermes
or or view top insider-buying stocks.

How do I buy shares of Alkermes?

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $24.42.

How much money does Alkermes make?

Alkermes has a market capitalization of $3.92 billion and generates $1.04 billion in revenue each year. The company earns $-110,860,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.

How many employees does Alkermes have?

Alkermes employs 2,245 workers across the globe.

What is Alkermes' official website?

The official website for Alkermes is

Where are Alkermes' headquarters?

Alkermes is headquartered at 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4.

How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]

This page was last updated on 6/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.